Study M286

Study name

Kondo DG 2011

Title

Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study

Overall design

The aims of this study were to obtain pilot data for creatine augmentation in this population; and to demonstrate the feasibility of pre- and post-treatment 31-Phosphorus magnetic resonance spectroscopy (31P MRS) brain scans for in vivo measurement of bioenergetic neurometabolites. Female adolescents (depression group, n = 5) who had been on fluoxetine for >= 8 weeks, but continued meet diagnostic criteria for MDD with a Children's Depression Rating Scale-Revised (CDRS-R) raw score >= 40 were recruited. Treatment response was measured with the CDRS-R. 31P MRS brain scans were performed at baseline, and repeated following adjunctive creatine 4 g daily for 8 weeks. For comparison, healthy female adolescents (control group, n = 10) underwent identical brain scans performed 8 weeks apart. For each metabolite, the peak area was normalized by the total phosphorous signal.

Study Type

Type1;

Type2;

Data available

Unavailable

Organism

Human;

Categories of depression

Depressive disorder; Pediatric depression; Pediatric depression;

Criteria for depression

DSM-IV diagnosed MDD, CDRS-R >= 40

Sample size

11

Tissue

Central; Brain; Brain;

Platform

MRS; MRS: Siemens 3 Tesla MRI scanner (Siemens AG, Munich, Germany);

PMID

21831448

DOI

10.1016/j.jad.2011.07.010

Citation

Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord 2011;135(1-3):354-61.

Metabolite

Phosphocreatine;